CN106148529B - LncRNA marker related to gastric cancer, special detection primer, detection method, kit and application thereof - Google Patents
LncRNA marker related to gastric cancer, special detection primer, detection method, kit and application thereof Download PDFInfo
- Publication number
- CN106148529B CN106148529B CN201610550253.5A CN201610550253A CN106148529B CN 106148529 B CN106148529 B CN 106148529B CN 201610550253 A CN201610550253 A CN 201610550253A CN 106148529 B CN106148529 B CN 106148529B
- Authority
- CN
- China
- Prior art keywords
- linp1
- lncrna
- expression level
- gapdh
- gastric cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an LncRNA marker related to gastric cancer, a special detection primer, a detection method, a kit and application thereof. The LncRNA marker is named as LINP1, the nucleotide sequence of the LncRNA marker is shown as SEQ NO.1 in a sequence table, the nucleotide sequence of an upstream primer (LINP1-F) of the LncRNA marker is shown as SEQ NO.2 in the sequence table, and the nucleotide sequence of a downstream primer (LINP1-R) of the LncRNA marker is shown as SEQ NO.3 in the sequence table, wherein the primer is used for detecting LINP 1. The LINP1 provided by the invention is a long-chain non-coding RNA particularly related to gastric cancer, the expression level of LINP1 can be detected from tissues with high specificity, the detection operation is simple and convenient, the quantification is accurate, the clinical judgment of the postoperative recurrence rate and the prognosis effect of a gastric cancer patient is facilitated, and the LINP1 can be used for screening gastric cancer treatment drugs and providing help for the development of new drugs.
Description
Technical Field
The invention belongs to the field of molecular biology, and relates to a long-chain non-coding RNA (LncRNA) marker and application thereof, in particular to a LncRNA marker related to gastric cancer, and a special detection primer, a detection method, a kit and application thereof.
Background
Gastric cancer is one of common malignant tumors, nearly one million new gastric cancers occur every year around the world, and China accounts for about half of the new gastric cancers. The mortality rate of the gastric cancer is the third of the mortality rate related to the cancer, and the relative survival rate of the gastric cancer in 5 years standardized by the age in China is only 27.4 percent, thus seriously threatening the health of people. Although comprehensive treatment modes such as new adjuvant chemotherapy and the like have been advanced sufficiently in recent years, surgery is still the most important treatment means for gastric cancer, but postoperative recurrence and metastasis are important factors affecting survival of patients and are clinical problems. Therefore, patient survival would certainly benefit if relapse or metastasis could be predicted early and the necessary therapeutic intervention could be taken.
There are many factors influencing gastric cancer prognosis, and the current main method for judging gastric cancer prognosis is the traditional staging method of the international cancer union (TNM) to estimate the survival time without recurrence. However, in clinical work, classical TNM staging cannot explain the same stage but with a distinct prognosis and cannot judge early postoperative recurrence. Currently, clinicians are perfecting the eighth version of the gastric cancer TNM staging system to assess prognosis. Meanwhile, basic researchers also consider tumor heterogeneity and search for new molecular indexes for judging prognosis as a supplement to a TNM pathological staging system. The occurrence and development of gastric cancer involve mutations in oncogenes and tumor suppressor genes, and also involve changes in epigenetics and the like. Therefore, research on molecular biological markers related to diagnosis and prognosis of gastric cancer has become an important research point.
At present, many research reports on gastric cancer tumor molecular markers exist, except for traditional tumor markers of carcinoembryonic antigen (CEA) and the like, research on hot molecular markers of HER2 and the like also has certain significance on gastric cancer prognosis judgment at present, but the above molecular markers mostly focus on research on different tumor stages, influence of lymph node metastasis and infiltration depth, research on molecular markers with different prognoses due to the lack of the same pathological stage, the same operation formula and a postoperative treatment scheme, and the lack of molecular markers with high specificity and sensitivity to predict the occurrence, development and prognosis of gastric cancer.
Long non-coding RNA (LncRNA) refers to nucleotide with length larger than 200bp, and RNA with gene expression regulation function and incapable of coding and producing protein. LncRNA participates in biological behaviors such as generation, development, invasion and metastasis of gastric cancer, and the action mode of the LncRNA comprises epigenetic regulation, transcriptional level regulation and post-transcriptional level regulation. If LncRNA which is specifically or abnormally expressed after early relapse and prognosis after gastric cancer operation can be screened out to be used as a biomarker, a related reagent and a kit are developed, the expression quantity of the LncRNA biomarker can be accurately detected, and the prediction of the early relapse and prognosis after gastric cancer operation can be powerfully promoted. In addition, the abnormally expressed LncRNA can influence the migration and metastasis of gastric cancer cells, and is helpful for discovering small molecule drugs with potential therapeutic value.
Disclosure of Invention
The first object of the present invention is to provide an LncRNA marker associated with gastric cancer.
The LncRNA marker related to the gastric cancer, which is provided by the invention, is named as LINP1, is particularly related to postoperative recurrence and prognosis of the gastric cancer, and has a nucleotide sequence shown as SEQ NO.1 in a sequence table or a nucleotide sequence shown as SEQ ID NO: l has more than 90% of homology and is related to postoperative recurrence and prognosis of gastric cancer, or is a nucleotide sequence shown in SEQ ID NO: l is obtained by modifying the nucleotide sequence shown by the general formula I through sulfo modification or/and methoxyl modification.
The second object of the present invention is to provide a primer for detecting the LncRNA marker LINP 1.
The nucleotide sequence of an upstream primer (LINP1-F) of the primer for detecting the marker LINP1 is shown as SEQ NO.2 in a sequence table, and the nucleotide sequence of a downstream primer (LINP1-R) of the primer for detecting the marker LINP1 is shown as SEQ NO.3 in the sequence table.
For convenient detection, GAPDH can be used as an internal reference, the nucleotide sequence of which is shown as SEQ NO.4 in the sequence table, and a primer for detecting the GAPDH internal reference, the nucleotide sequence of an upstream primer (GAPDH-F) thereof is shown as SEQ NO.5 in the sequence table, and the nucleotide sequence of a downstream primer (GAPDH-R) thereof is shown as SEQ NO.6 in the sequence table.
The third purpose of the invention is to provide a kit for detecting the expression level of the marker LINP 1.
the kit for detecting the expression level of the marker LINP1 comprises a primer of the marker LINP1 and a primer for detecting a GAPDH internal reference.
Specifically, the kit comprises the following reagents for a 20 μ L PCR reaction system: 11. mu.L of a 2 XPCR premix (containing 2.5U of Taq DNA polymerase, 1.5mmol/L of MgCl2, 100. mu. mol/L of dNTPs and 2.0mmol/L of SYBR Green I), 1. mu.L of an upstream primer (10. mu.M), 1. mu.L of a downstream primer (10. mu.M), and 7. mu.L of RNase-free water.
The fourth purpose of the invention is to provide a method for detecting the expression level of the marker LINP1 for non-diagnostic use.
The method for detecting the expression level of the marker LINP1 provided by the invention can comprise the following steps:
1) Extracting total RNA of tumor tissues and normal tissues to be detected, and carrying out reverse transcription to synthesize cDNA;
2) Carrying out real-time fluorescent quantitative PCR detection on an LncRNA marker LINP1 under the guidance of primers LINP1-F and LINP1-R and carrying out real-time fluorescent quantitative PCR detection on a GAPDH internal reference under the guidance of primers GAPDH-F and GAPDH-R by taking cDNA as a template;
3) The expression level of LncRNA marker LINP1 was calculated by relative quantification using the formula F ═ 2- Δ Δ ct, where Δ Δ ct ═ is (ct average value of LINP1 in tumor tissue-ct average value of GAPDH in tumor tissue) - (ct average value of LINP1 in control normal tissue-ct average value of GAPDH in control normal tissue).
In the detection method, the 20 μ L PCR reaction system in step 2) is: 11 uL of 2 XPR pre-mixed solution (including 2.5U Taq DNA polymerase, 1.5mmol/L MgCl2, 100 umol/L dNTPs and 2.0mmol/L SYBR Green I), 1 uL cDNA, 1 uL upstream primer (10 uM), 1 uL downstream primer (10 uM), and 7 uL RNase-free water; the PCR reaction conditions are as follows: firstly, the temperature is 95 ℃ for 30 seconds; then 95 ℃ for 5 seconds and 60 ℃ for 30 seconds for 40 cycles.
The primers LINP1-F and LINP1-R, the primers GAPDH-F and GAPDH-R and the application of the kit in detecting the expression level of the LncRNA marker LINP1 also belong to the content of the invention.
the LncRNA marker LINP1 related to gastric cancer and the kit for detecting the expression level of LINP1 can be used for judging the postoperative recurrence rate and the prognosis effect of gastric cancer, can also be used for screening gastric cancer treatment medicines, and belongs to the content of the invention for non-diagnosis purposes.
The application I is the application of the LncRNA marker LINP1 in judging the postoperative recurrence rate and prognosis effect of gastric cancer, the application is to detect the expression quantity of LINP1, the recurrence rate and prognosis effect are judged after the expression quantity value is compared with a threshold value, if the expression quantity of LINP1 is less than 7.65, the recurrence rate is high, the prognosis is poor, and if the expression quantity of LINP1 is more than 7.65, the recurrence rate is low, and the prognosis is good. The present invention does not include a limitation that the expression level of LINP1 is used as a direct determination index for the presence or absence of gastric cancer.
Secondly, the LncRNA marker LINP1 is applied to screening of gastric cancer treatment drugs, the application is to detect the expression quantity of LINP1, the drug sensitivity evaluation is made after the expression quantity value is compared with a threshold value, if the expression quantity of LINP1 is less than 7.65, the receptor is not sensitive to the drugs, and the drugs are not recommended; if the expression level of LINP1 is greater than 7.65, the receptor is sensitive to the drug, and the drug is recommended.
In conclusion, the invention provides an LncRNA marker related to gastric cancer, a special detection primer, a detection method, a kit and application thereof. The invention has the following advantages:
1) The proposed LINP1 is a long-chain non-coding RNA particularly related to gastric cancer, and the expression level of LINP1 can be detected from tissues with high specificity, thereby being beneficial to clinically judging the postoperative recurrence rate and prognosis of gastric cancer patients.
2) Simple operation and accurate quantification.
3) LINP1 can also be used for screening gastric cancer treatment drugs (especially small molecule drugs), and can be combined with animal models or clinical data to evaluate the sensitivity of receptors to drugs, thereby providing help for new drug development.
the present invention will be described in further detail with reference to specific examples.
Drawings
FIG. 1 shows the results of measurement of the expression level of LncRNA marker LINP1 associated with gastric cancer;
FIG. 2 is a ROC curve showing the expression level of LINP 1;
FIG. 3 is a graph of recurrence-free survival of patients with LINP1 expression;
FIG. 4 is a graph showing the result of measuring the expression level of LncRNA marker LINP1 associated with gastric cancer in example 5;
FIG. 5 is a ROC curve showing the expression level of LINP1 in example 5.
Detailed Description
The methods used in the following examples are conventional unless otherwise specified, and specific procedures can be found in: molecular Cloning: A Laboratory Manual (Sambrook, J., Russell, David W., Molecular Cloning: A Laboratory Manual, 3rd edition, 2001, NY, Cold Spring Harbor).
The percentage concentration is a mass/mass (W/W, unit g/100g) percentage concentration, a mass/volume (W/V, unit g/100mL) percentage concentration, or a volume/volume (V/V, unit mL/100mL) percentage concentration, unless otherwise specified.
the various biological materials described in the examples are obtained by way of experimental acquisition for the purposes of this disclosure and should not be construed as limiting the source of the biological material of the invention. In fact, the sources of the biological materials used are wide and any biological material that can be obtained without violating the law and ethics can be used instead as suggested in the examples.
The primers used were synthesized by Shanghai Biotech.
The embodiments are provided in order to provide detailed embodiments and specific procedures, which will help understanding of the present invention, but the scope of the present invention is not limited to the following embodiments.
example 1 obtaining LncRNA marker LINP1 related to gastric cancer, GAPDH internal reference and detection primer thereof
First, LncRNA marker LINP1 related to gastric cancer and design of detection primer thereof
The LncRNA marker related to the gastric cancer provided by the invention is named as LINP1, and the nucleotide sequence of the LncRNA marker is shown as SEQ NO.1 in the sequence table.
The screening process of LINP1 is as follows:
1. Tumor tissue samples of patients with the same pathological stage, surgical plan and postoperative treatment but distinct prognosis were selected, and normal tissue above 5cm of the margin of the cancer focus of the same patient was selected as control.
2. RNA was extracted from tumor tissues and normal controls.
3. The cDNA is obtained by reverse transcription.
4. And (3) carrying out real-time fluorescent quantitative PCR reaction on the reverse transcription product, screening LncRNA with obvious difference, carrying out LncRNA expression statistical analysis, and finally preferably obtaining LINP1, which is shown in SEQ NO.1 in the sequence table.
The invention further identifies, based on the LINP1 marker, primers for detecting the marker LINP1, the sequences of which are as follows:
Upstream primer (LINP 1-F): 5'-agccggtccagtacaccttt-3' (SEQ NO.2 of sequence Listing)
Downstream primer (LINP 1-R): 5'-ggaaagcaccgtctgttgtt-3' (SEQ NO.3 of the sequence Listing).
Second, GAPDH internal reference and its detecting primer design
for convenient detection, GAPDH can be used as an internal reference, and the nucleotide sequence of the GAPDH is shown as SEQ NO.4 in a sequence table.
The primers used for detecting the GAPDH internal reference have the following sequences:
Upstream primer (GAPDH-F): 5'-ccgggaaactgtggcgtgatgg-3' (SEQ NO.5 of sequence Listing)
Downstream primer (GAPDH-R): 5'-aggtggaggagtgggtgtcgctgtt-3' (SEQ NO.6 of the sequence Listing).
Example 2 detection of the expression level of marker LINP1
The method for detecting the expression level of the marker LINP1 comprises the following steps:
1) Extracting total RNA of tumor tissue and normal tissue to be detected, and synthesizing cDNA by reverse transcription, comprising the following steps:
1.1 selection of samples
Selecting 50 paraffin specimens which have the same pathological stages and obviously different prognosis survival and are collected in the 2005-2006 period of the general hospital of the liberation force, wherein the 50 specimens are the paraffin prepared by firstly removing the tumor sample from the primary focus. In 50 cases, no distant metastasis is detected through physical examination and imaging diagnosis before operation, radiation therapy or chemotherapy is not received before operation, open radical operation therapy is adopted, pathological examination after operation is ulcer-type low-differentiation adenocarcinoma, invasion to muscle layers and no lymph node metastasis, 50 cases are T2N0M0 according to staging standards of the seventh edition of the International anticancer Union, clinical staging is IB, but obvious difference exists in the future, 25 cases are healthy after 5 years, and 25 cases die after 5 years.
1.2 Total RNA was extracted from paraffin-embedded tumor and normal tissues using Trizol method, and the procedure was performed according to the instructions of Reagent kit (from Life Technologies). The total RNA purity and concentration were determined by measuring the absorbance at 230,260,280 using a spectrophotometer, respectively.
1.3 reverse transcription reaction was carried out using a reverse transcription kit (purchased from Takara Co., Ltd.) according to the kit instructions, and 10. mu.L of a reaction system was composed of: mu.L 5 XPrimeScript Buffer, 0.5. mu.L PrimeScript RT Enzyme Mix I, 0.5. mu.L 50. mu.M Oligo dT Primer, 0.5. mu.L 100. mu.M Random 6mers, 1.5. mu.L RNA, supplemented with RNase-free water to 10. mu.L, reaction conditions were: 15 minutes at 37 ℃ and then 5 seconds at 85 ℃ and finally 4 ℃. After completion of the reaction, the reverse transcription product was placed on ice for use.
2) Using cDNA as a template, conducting real-time fluorescent quantitative PCR detection of LncRNA marker LINP1 under the guidance of primers LINP1-F and LINP1-R, conducting real-time fluorescent quantitative PCR detection of GAPDH reference under the guidance of primers GAPDH-F and GAPDH-R, wherein 20 uL of PCR reaction system is as follows: 11 uL of 2 XPR pre-mixed solution (including 2.5U Taq DNA polymerase, 1.5mmol/L MgCl2, 100 umol/L dNTPs and 2.0mmol/L SYBR Green I), 1 uL cDNA, 1 uL upstream primer (10 uM), 1 uL downstream primer (10 uM), and 7 uL RNase-free water; the PCR reaction conditions are as follows: firstly, the temperature is 95 ℃ for 30 seconds; then 95 ℃ for 5 seconds and 60 ℃ for 30 seconds for 40 cycles.
3) The expression level of LncRNA marker LINP1 was calculated by relative quantification using the formula F ═ 2- Δ Δ ct, where Δ Δ ct ═ is (ct average value of LINP1 in tumor tissue-ct average value of GAPDH in tumor tissue) - (ct average value of LINP1 in control normal tissue-ct average value of GAPDH in control normal tissue).
The detection result is shown in fig. 1, LINP1 is up-regulated in a sample with 5-year health and better prognosis after gastric cancer operation, the expression level is 12.86 +/-2.51, LINP1 is down-regulated in a sample with early relapse and poorer prognosis after gastric cancer operation, the expression level is 4.27 +/-1.26, and the difference has statistical significance.
An ROC curve is constructed, as shown in FIG. 2 (the curve with points in the graph is coincident with the upper limit and the left limit of the square, the curve with points is the ROC curve; 7.65 is the point of the arc top of the curve, namely the point closest to the upper left corner of the square and is calculated in software), and by taking 7.65 as a boundary value, patients with better prognosis and patients with poor prognosis in the same stage can be well distinguished, and the sensitivity reaches 100%.
And (4) conclusion: if the expression level of LINP1 is less than 7.65, the recurrence rate is high, and the prognosis is poor; if the expression level of LINP1 is more than 7.65, the recurrence rate is low and the prognosis is good.
example 3 analysis of LINP1 expression level and Risk score of postoperative recurrence of gastric cancer
The SPSS 22.0 software is used for establishing a database for the detection results of the example 2 and analyzing the database, and Kaplan-Meier is used for analyzing the relapse-free survival curve of the patient with the LINP1 expression amount.
as shown in FIG. 3, with P <0.05 as the test level, it can be seen that the patient survived longer when LINP1 expression was high, and in contrast, relatively shorter when LINP1 expression was low, indicating that the amount of LINP1 expression has a significant correlation with the patient's relapse-free survival time (P0.017).
COX one-way correlation analysis was performed on gastric cancer patients' age, sex, tumor size, degree of differentiation, as well as LINP1 expression and relapse-free survival time. The analysis results are shown in table 1, and it can be seen that the larger the tumor is, the lower the differentiation degree is, and the lower the expression of LINP1 is a risk factor for poor prognosis of the patient, i.e. when one of the above factors exists, the survival time of the patient is shorter, which indicates that the tumor size, the differentiation degree and the expression level of LINP1 are obviously related to the recurrence survival time of the patient.
TABLE 1 analysis results of COX single-factor correlation of age, sex, tumor size, degree of differentiation, and LINP1 expression and recurrence-free survival time of gastric cancer patients
The above statistically significant indicators were included in a COX multifactor analysis model. The analysis results are shown in table 2, and it can be seen that the survival time of the patients is shorter when the differentiation degree is low and the expression of LINP1 is low after the multi-factor correction, and the low expression of LINP1 is a poor prognostic factor of the survival time of the patients without relapse, and the risk is 1.663.
TABLE 2 analysis of COX severity factor correlation results for gastric cancer patients with tumor size, degree of differentiation, LINP1 expression and relapse-free survival time
example 4 preparation of kit for detecting expression level of marker LINP1
The kit for detecting the expression level of the LncRNA marker LINP1 related to the gastric cancer, provided by the invention, comprises a primer of the marker LINP1 and a primer for detecting GAPDH internal reference.
The kit also comprises the following reagents for a 20 μ L PCR reaction system: 11. mu.L of a 2 XPCR premix (containing 2.5U of Taq DNA polymerase, 1.5mmol/L of MgCl2, 100. mu. mol/L of dNTPs and 2.0mmol/L of SYBR Green I), 1. mu.L of an upstream primer (10. mu.M), 1. mu.L of a downstream primer (10. mu.M), and 7. mu.L of RNase-free water.
See example 2 for methods of use of the kits of the invention.
Example 5 application of LINP1 marker in screening gastric cancer treatment drugs
Selecting a sample: 20 patients receiving neoadjuvant chemotherapy from 2013 to 2014 are selected, wherein 10 patients are sensitive to the chemotherapy drugs and completely relieved in pathology, and 10 patients are insensitive to the chemotherapy drugs and evaluated as disease progression in pathology. Two groups of people are taken to receive tumor tissues before chemotherapy, and the kit is used for detecting the expression level of LINP1 in the tissues, and the using method is shown in example 2.
The detection result is shown in figure 4, the expression of LINP1 is up-regulated in patients sensitive to the chemotherapeutic drug, the expression level is 9.82 +/-0.89, the expression level of LINP1 is down-regulated in patients insensitive to the chemotherapeutic drug, the expression level is 4.85 +/-0.67, and the difference has statistical significance.
constructing the ROC curve, as shown in FIG. 5 (same as that described in FIG. 2), with a cut-off of 7.65, can distinguish between drug-sensitive and drug-insensitive patients, with a sensitivity of up to 90%.
And (4) conclusion: if the expression level of LINP1 is less than 7.65, the patient is not sensitive to the chemotherapeutic drug, and the chemotherapeutic drug is not recommended; if the expression level of LINP1 is greater than 7.65, the patient is sensitive to the chemotherapeutic drug, and the chemotherapeutic drug is recommended.
By using the method of the embodiment, different chemotherapeutic drugs can be screened by combining with an animal model, the LINP1 expression level of the animal model (receptor) is detected, the drug sensitivity evaluation is performed after the expression level value is compared with a threshold value, if the LINP1 expression level is less than 7.65, the receptor is not sensitive to the drug, and the drug is filtered and is not recommended; if the expression level of LINP1 is greater than 7.65, it indicates that the receptor is sensitive to the drug, and the drug is selected and recommended. Therefore, the method can help drug developers to acquire new drugs with potential value in advance.
Claims (7)
- The application of LncRNA LINP1 in preparing an LncRNA marker related to gastric cancer prognosis, wherein the nucleotide sequence of LncRNA LINP1 is shown as SEQ No.1 in a sequence table, the expression level of LncRNA LINP1 is calculated by a relative quantification method, and the expression is F ═ 2- Δ ct, wherein Δ Δ ct ═ is calculated (ct average value of LINP1 in tumor tissue-ct average value of GAPDH in tumor tissue) - (ct average value of LINP1 in control normal tissue-ct average value of GAPDH in control normal tissue); if the expression level of LINP1 is less than 7.65, the recurrence rate is high, and the prognosis is poor; if the expression level of LINP1 is more than 7.65, the recurrence rate is low and the prognosis is good.
- 2. The use of claim 1, wherein the expression level of LncRNA LINP1 is detected by a kit, wherein the kit comprises a primer for detecting LncRNA LINP1, the nucleotide sequence of its upstream primer LINP1-F is shown as SEQ No.2 in the sequence list, and the nucleotide sequence of its downstream primer LINP1-R is shown as SEQ No.3 in the sequence list.
- 3. The use of claim 2, wherein the kit further comprises a primer of a GAPDH internal reference for detecting the expression level of LncRNA LINP1, wherein the nucleotide sequence of an upstream primer GAPDH-F is shown as SEQ No.5 in the sequence listing, the nucleotide sequence of a downstream primer GAPDH-R is shown as SEQ No.6 in the sequence listing, and the nucleotide sequence of the GAPDH internal reference is shown as SEQ No.4 in the sequence listing.
- 4. the use according to claim 3, wherein the kit comprises the following reagents for a 20 μ L PCR reaction system: 11 mul of 2 XPCR premix, 1 mul of 10 mul upstream primer, 1 mul of 10 mul downstream primer, and 7 mul of RNase-free water; wherein the 2 XPCR premix comprises 2.5U Taq DNA polymerase, 1.5mmol/L MgCl2, 100. mu. mol/L dNTPs and 2.0mmol/L SYBR Green I.
- 5. The use according to claim 4, wherein said method for detecting the expression level of LncRNA LINP1, wherein said method is a method for non-diagnostic purposes, comprising the steps of:1) extracting total RNA of tumor tissues and normal tissues to be detected, and carrying out reverse transcription to synthesize cDNA;2) Carrying out real-time fluorescent quantitative PCR detection on LncRNA LINP1 under the guidance of the primers LINP1-F and LINP1-R and carrying out real-time fluorescent quantitative PCR detection on GAPDH internal reference under the guidance of the primers GAPDH-F and GAPDH-R by taking cDNA as a template;3) Expression of LncRNA LINP1 was calculated by relative quantification using the formula F ═ 2- Δ Δ ct, where Δ Δ ct ═ is (ct average for LINP1 in tumor tissue-ct average for GAPDH in tumor tissue) - (ct average for LINP1 in control normal tissue-ct average for GAPDH in control normal tissue).
- 6. The use of claim 5, wherein the PCR conditions in step 2) are: firstly, the temperature is 95 ℃ for 30 seconds; then 95 ℃ for 5 seconds and 60 ℃ for 30 seconds for 40 cycles.
- 7. The use of claim 1, wherein the use is for screening a drug for treating gastric cancer by using the expression level of LncRNA LINP1, and the drug sensitivity is evaluated by comparing the expression level with a threshold, and if the expression level of LncRNA LINP1 is less than 7.65, the drug is not recommended and the receptor is not sensitive to the drug; if the expression level of LncRNA LINP1 is greater than 7.65, the receptor is sensitive to the drug, and the drug is recommended.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610550253.5A CN106148529B (en) | 2016-07-13 | 2016-07-13 | LncRNA marker related to gastric cancer, special detection primer, detection method, kit and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610550253.5A CN106148529B (en) | 2016-07-13 | 2016-07-13 | LncRNA marker related to gastric cancer, special detection primer, detection method, kit and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106148529A CN106148529A (en) | 2016-11-23 |
| CN106148529B true CN106148529B (en) | 2019-12-06 |
Family
ID=58061623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610550253.5A Expired - Fee Related CN106148529B (en) | 2016-07-13 | 2016-07-13 | LncRNA marker related to gastric cancer, special detection primer, detection method, kit and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106148529B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106811525A (en) * | 2017-02-10 | 2017-06-09 | 南方医科大学南方医院 | A kind of kit and system for predicting the recurrence of III phase patients with gastric cancer early postoperation |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107236817B (en) * | 2017-07-19 | 2020-12-25 | 广州医科大学附属第五医院 | LncRNA ENST00000424523.1 and application of LncRNA ENST00000424523.1 gene in diagnostic and therapeutic drugs |
| CN107475386B (en) * | 2017-08-22 | 2018-08-21 | 固安博健生物技术有限公司 | Long-chain non-coding RNA marker for diagnosis and treatment osteosarcoma |
| CN107727859B (en) * | 2017-10-06 | 2019-05-31 | 上海核盾生物科技有限公司 | A kind of serum I FN- γ and LncRNAs composition is used to prepare the purposes of cancer diagnosis reagent box |
| CN111500729B (en) * | 2020-05-14 | 2022-02-01 | 中国人民解放军总医院 | Application of plasma lnc-SCA7 in preparation of biomarker for judging whether patient is sensitive to neoadjuvant chemotherapy |
| CN114350796B (en) * | 2021-12-17 | 2023-05-05 | 南方医科大学 | Application of LINP1 in diagnosis and treatment of skin squamous cell carcinoma |
| CN116590409A (en) * | 2022-12-30 | 2023-08-15 | 中国人民解放军总医院第一医学中心 | Use of lnc-MILIP as biomarker for predicting susceptibility to gastric cancer immunotherapy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105200157A (en) * | 2015-11-04 | 2015-12-30 | 中国人民解放军总医院 | Plasma miRNA (micro-ribonucleic acid) biologic marker assemblage for gastric cancer, application of assemblage and early diagnosis kit for gastric cancer |
-
2016
- 2016-07-13 CN CN201610550253.5A patent/CN106148529B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105200157A (en) * | 2015-11-04 | 2015-12-30 | 中国人民解放军总医院 | Plasma miRNA (micro-ribonucleic acid) biologic marker assemblage for gastric cancer, application of assemblage and early diagnosis kit for gastric cancer |
Non-Patent Citations (2)
| Title |
|---|
| Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer;Youyou Zhang ET AL;《nature structural & molecular biology》;20160425;第23卷(第6期);摘要，523页 * |
| Noncoding RNA joins Ku and DNA-PKcs for DNA-break resistance in breast cancer;Susan P Lees-Miller, Tara L Beattie & John A Tainer;《nature structural & molecular biology》;20160630;第23卷(第6期);509-510 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106811525A (en) * | 2017-02-10 | 2017-06-09 | 南方医科大学南方医院 | A kind of kit and system for predicting the recurrence of III phase patients with gastric cancer early postoperation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106148529A (en) | 2016-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106148529B (en) | LncRNA marker related to gastric cancer, special detection primer, detection method, kit and application thereof | |
| Filella et al. | Emerging biomarkers in the diagnosis of prostate cancer | |
| CA2957396C (en) | Method of determining pik3ca mutational status in a sample | |
| TWI540320B (en) | Molecular markers for lung and colorectal carcinomas | |
| JP6989863B2 (en) | How to diagnose colorectal cancer | |
| Molinari et al. | Biomarkers and molecular imaging as predictors of response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer | |
| WO2014135669A1 (en) | Egfr mutation blood testing | |
| JP2019527544A (en) | Molecular marker, reference gene, and application thereof, detection kit, and detection model construction method | |
| CN110484624B (en) | Gastric cancer biomarker based on peripheral blood and detection method and application thereof | |
| CN107532208B (en) | Compositions and methods for determining prognosis of endometrial cancer | |
| CN104293910B (en) | One group of assessment breast cancer molecular parting gene group and detection kit thereof | |
| D’Amico et al. | The use of liquid biopsy in early breast cancer: Clinical evidence and future perspectives | |
| CN103773837A (en) | Fluorescent quantitation PCR detection kit and detection method for PIK3CA (phosphatidylinositol3-kinase catalytic alpha) gene mutations | |
| Nair et al. | Genomic profiling of bronchoalveolar lavage fluid in lung cancer | |
| Liu et al. | Protocadherin γ-A7 is down-regulated in colorectal cancer and associated with the prognosis in patients with wild-type KRAS | |
| Rose et al. | Circulating and urinary tumour DNA in urothelial carcinoma—upper tract, lower tract and metastatic disease | |
| EP3444362B1 (en) | Circulating mirnas as early detection marker and prognostic marker | |
| Constâncio et al. | MiRNA biomarkers in cancers of the male reproductive system: are we approaching clinical application? | |
| Lerebours et al. | Hemoglobin overexpression and splice signature as new features of inflammatory breast cancer? | |
| CN103074431A (en) | Special primer, kit and method for testing minRNA-128 in colorectal cancer serum | |
| CN106119347B (en) | The primer and kit of colorectal cancer transfer detection based on serum exosomal microRNAs | |
| CN104450702B (en) | A kind of Serum miRNA biomarker composition and application | |
| Kessler et al. | Improving cancer detection and treatment with liquid biopsies and ptDNA | |
| CN108753981A (en) | Application of the quantitative detection of HOXB8 genes in colorectal cancer Index for diagnosis | |
| CN108424962A (en) | The miRNA detection markers and its diagnostic kit of mesangial proliferative glomerulonephritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191206 Termination date: 20210713 |